en.aazsante.fr

The Largest Portal Of Health And Quality Of Life.

Anvisa releases medicines for type 2 diabetes

Anvisa releases medicines for type 2 diabetes

On Monday (17), Anvisa approved a new medication for type 2 diabetes.

Type 2 diabetes is a chronic disease that affects how the body metabolizes glucose, the body's primary source of energy. A person with type 2 diabetes may have a resistance to the effects of insulin - the hormone that regulates the entry of sugar into cells - or does not produce enough insulin to maintain a normal glucose level. When untreated, diabetes can be fatal.

Unlike people with type 1 diabetes, people with type 2 diabetes produce insulin. However, can the body create insulin resistance? that is, it does not respond the way it should to the action of insulin and does not use it correctly. It can also happen that the type 2 diabetes patient does not produce enough insulin to meet the demands of his or her body. In this process, insufficient insulin can not carry all the sugar into the cells, and it eventually accumulates in the blood.

According to Anvisa, the drug, called Soliqua, aims to improve glycemic control in the body.

The drug is now used for a price definition that will be approved by a body linked to the Ministry of Health.


São Paulo extends flu vaccination until June 6

São Paulo extends flu vaccination until June 6

The State Department of Health of São Paulo has decided to continue the vaccination campaign against influenza in the municipalities of São Paulo until next Wednesday, June 6. The objective is to immunize the elderly with 60 years or more, children between six months and less than two years of age, pregnant at any stage of pregnancy, indigenous and health workers.

(Health)

The World Health Organization recommends periodic treatment for people at increased risk of parasites who are living in areas of higher prevalence.

The World Health Organization recommends periodic treatment for people at increased risk of parasites who are living in areas of higher prevalence.

The World Health Organization recommends the periodic treatment of people exposed to a greater risk of parasitoses living in areas of higher prevalence. This risk group includes children from 1 to 14 years of age and workers with occupational hazards such as miners and some farm workers. People in areas with a prevalence of parasites above 20% should receive treatment annually and if the prevalence is greater than 50% they should receive treatment every 6 months.

(Health)